HLAG antibody

Catalog No. ABIN94384

This Mouse Monoclonal antibody specifically detects HLAG in WB, IHC (fro) and IHC (p). It exhibits reactivity toward Human and has been mentioned in 4+ publications.

Quick Overview for HLAG antibody (ABIN94384)

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This HLAG antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: MEM-G-2

Product Details anti-HLAG Antibody

Purpose: Anti-HLA-G Purified

Specificity: The antibody MEM-G/2 recognizes an extracellular epitope on free heavy chain of all the HLA-G isoforms. HLA-G belongs to the MHC Class I molecules (MHC Class Ib, nonclassical) and it is expressed on the surface of trophoblast cells.

Cross-Reactivity (Details): Human

Purification: Purified by protein-A affinity chromatography.

Purity: > 95 % (by SDS-PAGE)

Immunogen: Bacterially expressed recombinant HLA-G heavy chain (denatured).

Isotype: IgG1

Application Details

Application Notes: Western blotting: Recommended dilution 1-2 μg/mL.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.

Storage: 4 °C

Storage Comment: Store at 2-8°C. Do not freeze.

References for anti-HLAG antibody (ABIN94384)

Kren, Slaby, Muckova, Lzicarova, Sova, Vybihal, Svoboda, Fadrus, Lakomy, Vanhara, Krenova, Sterba, Smrcka, Michalek: "Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: An unexpected prognostic significance?" in: Neuropathology : official journal of the Japanese Society of Neuropathology, (2010) (PubMed).

Le Discorde, Moreau, Sabatier, Legeais, Carosella: "Expression of HLA-G in human cornea, an immune-privileged tissue." in: Human immunology, Vol. 64, Issue 11, pp. 1039-44, (2003) (PubMed).

Poláková, Bandzuchová, Hofmeister, Weiss, Hutter, Russ: "Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients." in: Neoplasma, Vol. 50, Issue 5, pp. 331-8, (2003) (PubMed).

Boyson, Erskine, Whitman, Chiu, Lau, Koopman, Valter, Angelisova, Horejsi, Strominger: "Disulfide bond-mediated dimerization of HLA-G on the cell surface." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Issue 25, pp. 16180-5, (2002) (PubMed).

Target Details for HLAG

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Alternative Name: HLA-G

Background: Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.

Gene ID: 3135

UniProt: P17693

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response